Domain Associates

Domain Associates, L.L.C. is a private equity and venture capital firm specializing in investments in incubation, seed/start up, early venture, growth capital, PIPEs, and emerging growth companies. Within life sciences, it typically invests in healthcare companies with a focus on bio/pharmaceuticals, specialty pharmaceuticals, drug and device sectors, therapeutics and medical devices, biomaterials, bioinstrumentation, clinical diagnostics, tools and instrumentation, and healthcare IT (HCIT) and healthcare economics. It typically invests between $10 million and $25 million. The firm prefers to be a part of the first institutional financing round of a company and may also invest at other stages. It prefers to takes a board seat in its portfolio companies. The firm may also invest in public companies. Domain Associates, L.L.C. was founded in 1985 and is based in Princeton, New Jersey with an additional offices in San Diego, California; and Philadelphia, Pennsylvania.

James C. Blair

Partner

Jim Blair

Partner

Scott Borgstrom

IT Director

Brian Dovey

Partner

Brian Halak

Partner

Kim Kamdar

Partner

Lisa Kraeutler

MD of Finance and Administration

Harish Krishnaswamy

Associate

Debra Liebert

Investor

Dennis Podlesak

Advisory Partner

Jesse I. Treu

Partner Emeritus

Nicole Vitullo

Partner

Eckard Weber

Advisory Partner

305 past transactions

DiObex

Series B in 2007
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.

Adynxx, Inc.

Venture Round in 2012
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Tandem Diabetes Care, Inc. develops medical devices for the treatment of diabetes. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges. The company focuses on insulin infusion therapy. Tandem Diabetes Care, Inc. was incorporated in 2006 and is based in San Diego, California.

Somaxon Pharmaceuticals

Series C in 2005
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.

CoDa Therapeutics

Series B in 2011
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Receptor Biologix

Series A in 2005
Receptor Biologix develops receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases. The company is headquartered in Palo Alto, California.

Santarus

Series C in 2001
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Align Technology, Inc.

Series D in 2000
Align Technology, Inc. designs, manufactures, and markets the invisalign system for treating malocclusion or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. The company's products include Invisalign Full for the treatment of a range of malocclusions; Invisalign Express, a solution for less complex orthodontic cases; Invisalign Teen, which is designed to meet the specific needs of the non-adult comprehensive or teen treatment market; Vivera retainers that offer aesthetic retention solution for invisalign and non-invisalign patients; and Invisalign Assist, which is designed for general practitioners for selecting, monitoring, and finishing invisalign cases. It also offers ancillary products comprising cleaning material and adjusting tools for dental professionals. Align Technology distributes its products directly to orthodontists and general practitioner dentists in North America, Europe, the Asia Pacific, Latin America, and Japan. The company was founded in 1997 and is headquartered in Santa Clara, California.

Epic Sciences, Inc.

Series G in 2023
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Axial Biotherapeutics

Series A in 2016
Axial Biotherapeutics, Inc., a biopharmaceutical company, develops therapeutics for people with central nervous system diseases and disorders. It uses the microbiome discovery platform, which targets the gut-brain axis that provides the opportunity to generate a pipeline of new therapies for patients with neurological diseases and disorders. Axial Biotherapeutics, Inc. was formerly known as Neurobiotix Health, Inc. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Applied Proteomics

Series C in 2013
Applied Proteomics, Inc. develops noninvasive and blood-based tests that provide the proteins for monitoring and early detection of disease. It offers SimpliPro Colon test to deliver tests. The company was founded in 2006 and is based in San Diego, California.

Vascular Architects

Series D in 2003
Vascular Architects, Inc. designs, develops, manufactures and markets devices used in the treatment of vascular stenoses, occlusions and non-vascular obstructions. A key area of emphasis is the treatment of peripheral vascular disease, which manifests itself as a reduction or loss of blood flow due to the narrowing or closing of arteries. Vascular Architects was founded in October 1997 by Thomas J. Fogarty, M.D. Dr Fogarty is an internationally renowned surgeon, professor, inventor and entrepreneur who has founded or cofounded more than 25 start-up companies that develop innovative medical devices. He has authored or coauthored over 150 professional articles, is a member of 29 professional societies, and is an inventor on more than 65 U.S. patents. Their founder and management team form a highly experienced group of technical, clinical and business personnel. Key opinion leaders in the interventional and vascular surgery communities have been recruited to serve on the Vascular Architects' Scientific Advisory Board.

Celtaxsys

Series E in 2018
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

Peninsula Pharmaceuticals

Series B in 2002
A bio­pharmaceuti­cal company focused on the devel­opment and com­mer­cializa­tion of antibi­otics

Aradigm Corporation

Convertible Note in 2001
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

CellBiosciences

Series C in 2009
ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

Molecular Staging

Series D in 2000
Molecular Staging, Inc., a life sciences tool company, develops technologies for the detection and measurement of proteins and nucleic acids. It provides technologies for proteomics, genomics, pharmacogenomics, and diagnostics applications. The company’s products and services include protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins; whole-genome amplification that allows DNA samples as resources, enabling researchers to return to them for new tests or confirmatory diagnoses; and multiplexed diagnostics that enable earlier detection of disease.

Sebacia, Inc.

Series C in 2015
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.

The Foundry, LLC

Series A in 2010
The Foundry, LLC is the premier medical device company incubator. We work with inventors to rapidly transform their concepts into companies by providing an incomparable combination of leadership, an experienced, multi-disciplinary team, a state-of-the-art facility and an extensive funding network. The Foundry Team is comprised of veteran medical device entrepreneurs and investors with real world experience—and success—in developing world class medical device companies.

Adynxx, Inc.

Series B in 2017
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Cotera, Inc.

Venture Round in 2012
Cotera, Inc. designs and develops implants that shift muscles and tendons to redirect the forces they exert on joints. Its portfolio includes Latella device, an implant that is attached to the thigh bone (femur) through a surgical procedure for treating patients with medial knee pain due to osteoarthritis. The company was founded in 2011 and is based in Menlo Park, California.

Veracyte

Series C in 2013
Veracyte, Inc. develops diagnostics for thyroid and non-small cell lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. The company was incorporated in 2006 and is based in South San Francisco, California.

Atara Biotherapeutics

Venture Round in 2013
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Achaogen

Series B in 2006
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

BioNano Genomics

Series B in 2012
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

GeneOhm Sciences

Series C in 2005
GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.

NovaDigm Therapeutics

Series B in 2013
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.
Tandem Diabetes Care, Inc. develops medical devices for the treatment of diabetes. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges. The company focuses on insulin infusion therapy. Tandem Diabetes Care, Inc. was incorporated in 2006 and is based in San Diego, California.

Auxeris Therapeutics

Series A in 2004
Auxeris Therapeutics is a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases. The company develops drugs to treat fracture repair, spinal fusion, and bone diseases, including osteoporosis. Auxeris Therapeutics was founded in 2002 and is based in St. Louis, Missouri.

Atara Biotherapeutics

Series B in 2013
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Gene Sciences, Inc.

Series A in 2016
Gene Sciences operates as a biotech company. The company serves customers in the United States. Gene Sciences is committed to developing novel DNA targeted therapeutics that modulate gene expression for the treatment of human disease.

Alimera Sciences, Inc.

Series C in 2009
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Kona Medical

Series C in 2012
Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

Aspen Neuroscience

Seed Round in 2019
Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.

Adastra Pharmaceuticals

Venture Round in 2010
Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

Singular Genomics

Seed Round in 2016
Singular Genomics is a venture capital-backed biotech company in La Jolla, California. It fosters a dynamic, fast-paced, results-oriented environment where they offer employees the opportunity to make a significant impact in a rapidly expanding company. Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. The company is located in the center of the Biotech hub on the Torrey Mesa close to the Pacific Ocean and next door to prestigious institutions like the Salk Institute, Scripps, Sanford Burnham, and UCSD.

Iomai Corporation

Series C in 2003
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.
VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.

iScribe

Series D in 2001
iScribe is a healthcare technology company that is focused on the development of mobile, handheld, and wireless electronic prescribing technology solutions. iScribe was founded by David Levison in 1999.

Colorescience

Series B in 2014
Colorescience, Inc. produces and sells mineral-based cosmetics and sun screen products. It offers treatment products, UV protectors, primers, foundations, and enhancers. The company’s products are used to treat pigmentation, redness, dark circles, and aging problems, as well as sensitive, oily, and dry skin. It sells its products through a network of licensed physicians and luxury spas, retailers, and distributors; as well as online. The company was founded in 2000 and is based in Carlsbad, California. Colorescience, Inc. is a former subsidiary of SkinMedica, Inc.

Evoke Pharma, Inc.

Series A in 2007
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.

Somaxon Pharmaceuticals

Series B in 2004
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

NPS Pharmaceuticals, Inc.

Seed Round in 1992
NPS Pharmaceuticals, Inc., a biopharmaceutical company, provides therapeutic products for the treatment of gastrointestinal and endocrine disorders. The company offers Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support in the United States; and Revestive for the treatment of adult patients with SBS in the European Union. Its products also include Gattex/Revestive in pediatric SBS, which has completed an open-label 4-cohort study; Natpara, a bioengineered replica of human parathyroid hormone to control hypocalcemia in patients with hypoparathyroidism; and Natpar to treat hypoparathyroidism, as well as NPSP795, a calcilytic agent, which is in Phase IIA clinical stage for treating disorders involving increased calcium receptor activity. In addition, the company offers various royalty-based products, such as Sensipar and Mimpara for the treatment of primary and secondary hyperparathyroidism; Sensipa for treating hypercalcemia in parathyroid cancer; REGPARA for the treatment of secondary hyperparathyroidism; NUCYNTA and Nucynta ER for treating acute pain and chronic pain; and Ronacaleret that is in phase II clinical stage for treating stem cell mobilization. It has collaborations and license agreements with Amgen Inc., GlaxoSmithKline, Kyowa Hakko Kirin, Takeda GmbH, Janssen Pharmaceuticals, Inc., and Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd. The company was founded in 1986 and is based in Bedminster, New Jersey. As of February 21, 2015, NPS Pharmaceuticals, Inc. operates as a subsidiary of Shire Pharmaceutical Holdings Ireland Limited.

Alimera Sciences, Inc.

Series B in 2005
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Veracyte

Series B in 2010
Veracyte, Inc. develops diagnostics for thyroid and non-small cell lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. The company was incorporated in 2006 and is based in South San Francisco, California.

Carticept Medical

Series A in 2007
Carticept Medical develops therapies to improve the quality of life of patients with osteoarthritis or cartilage damage. Carticept currently offers a cartilage implant product and distributes Sonosite ultrasound products.

Esprit Pharma

Series B in 2007
Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.

Miramar Labs

Venture Round in 2016
Miramar Labs develops medical devices for aesthetic indications that treat primary axillary (underarm) hyperhidrosis in adults. The miraDry System cannot be used to treat hyperhidrosis elsewhere on the body, including the hands and feet. It was founded in 2006 and is based in Sunnyvale, California.

Axial Biotherapeutics

Series C in 2021
Axial Biotherapeutics, Inc., a biopharmaceutical company, develops therapeutics for people with central nervous system diseases and disorders. It uses the microbiome discovery platform, which targets the gut-brain axis that provides the opportunity to generate a pipeline of new therapies for patients with neurological diseases and disorders. Axial Biotherapeutics, Inc. was formerly known as Neurobiotix Health, Inc. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Xcel Pharmaceuticals

Venture Round in 2001
Xcel Pharmaceuticals are a specialty pharmaceutical company focused on prescription products that treat disorders of the central nervous system (CNS). They currently focus on neurology, a segment of the CNS market where a limited number of high-prescribing physicians write a significant number of the prescriptions for neurology products. Their product portfolio consists of four commercial products and two product candidates. Their commercial products include two epilepsy products, Diastat® and Mysoline®, and two migraine products, Migranal® and D.H.E. 45®. Their product candidates include MT 300™, a potential treatment for migraine, and retigabine, a potential treatment for epilepsy. their nationwide field sales organization promotes their products to high-prescribing epilepsy and migraine specialists. Their strategy is to increase prescription demand for Their lead products through targeted sales and marketing efforts, to successfully develop and commercialize Their late-stage development product candidates, to leverage Their CNS presence through the acquisition of additional late-stage development product candidates and commercial products, and to develop enhancements for Their current products. Their corporate infrastructure is designed to support Their field sales organization, to manage Their product development efforts, to identify and pursue the acquisition of additional late-stage development product candidates and commercial products, and to manage Their product enhancement efforts. They have developed valuable relationships with experts and third-party consultants that They intend to utilize for the advancement of late-stage development product candidates, including retigabine, through the development and regulatory approval process. They also utilize third parties to manufacture and distribute Their products and to support Their product development and enhancement efforts.

Glaukos Corporation

Series E in 2011
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Meritage Pharma

Series A in 2008
Meritage Pharma, Inc. develops prescription products for the treatment of gastrointestinal and atopic diseases. It offers budesonide, an active pharmaceutical ingredient and a glucocorticoid steroid for products that treat pediatric asthma, allergic rhinitis, and Crohn’s disease; and oral budesonide suspension, an oral formulation of budesonide for the potential treatment of adolescents and young adults with eosinophilic esophagitis, an allergic inflammation of the gastrointestinal tract. Meritage Pharma, Inc. was founded in 2008 and is based in San Diego, California.

Eddingpharm (Cayman)

Series B in 2010
Established in 2001, Eddingpharm’s vision and mission has always been to become China's leading supplier of patented drugs and branded drugs, bridge the gap between Chinese patients and global high quality medicines. They constantly acquired classic branded medicines from MNCs, that benefits Chinese patients through our effective operation cost management and expansion to the low-tier medical terminals. On the other hand, they keep exploring and innovating. Eddingpharm continuously introduce abroad patented drugs to China market, participate in international multi-center clinical trials and strive to realize simultaneous launch of new drugs in China and globally, providing physicians with more treatment options. Over the past few years, they rapidly expanded our business and strategically deployed resources in various fields. They are upgrading to a whole-industry-chain entity from sole in-licensing R&D and commercialization. Eddingpharm has nearly 1,000 professional representatives in 30 provinces across the country, with coverage of 19,000+ hospitals and 20,000+ pharmacies. Over the years, they have collaborated with multinational pharmaceutical companies, specialty pharmaceutical companies and leading R&D institutions to enrich our product portfolio by in-licensing patented drugs, setting up JV, gaining exclusive distribution rights and forming strategic alliances. Our focused therapy areas have been expanded to anti-biology, oncology, respiratory, cardiovascular and renal diseases. In addition, our several new drugs under development or regulatory registration are expected to be launched in the near future. The revolutionary product Vascepa® capsule is a single-molecule prescription product consisting of the icosapentaenoic acid commonly known as EPA in ethyl-ester form. Its ability has been verified that lowering triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. The ability of reducing residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, has been published in The New England Journal of Medicine in November 2018. Additional results and analysis of total recurrent events observed were subsequently published in the Journal of American College of Cardiology in March 2019. Recently, supplemental new drug application (sNDA) for Vascepa® capsules reducing cardiovascular risks has been accepted for filing and granted Priority Review designation by the US FDA. Eddingpharm has been granted the rights of development, commercialization and supply of VASCEPA® in mainland China, Hong Kong, Macau and Taiwan since 2015, also including the management and sponsor of pivotal clinical trials for registration. They have completed a pharmacokinetic (PK) study in China and a racial comparison study of PK characteristics between Chinese and American healthy subjects. Phase III clinical trial is currently in progress. "Professionalism, excellence, responsibility, and persistence" are the values of Eddingpharm. Our profession is related to life and health, professionalism is the fundamental principle. Excellence runs through every minute of our work. Responsibility is our attitude towards each task. In the face of our beliefs and missions, they will stick to persistence and never give up. They are moving towards the goal that Chinese patients benefit from the world's best medicines and cutting edge medical technology.

Beansprout.net

Series C in 2000
Beansprout offers customizable websites to pediatricians, licensed childcare distributors, and childcare resources. It builds an online hub to connect parents with their pediatricians as well as provides a forum for distributors of goods and services to the audiences. The company’s product, the Good Health Program, provides doctors with patient education tools that are placed in the examination rooms of select practices in the network. Beansprout is a U.S.-based company that was founded in 1998 and the company was acquired by Innovex on November 5, 2002.

Corthera

Series C in 2007
Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.

SkinMedica

Series E in 2006
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

Helixis

Series A in 2007
Helixis, Inc. is a company that develops low-cost molecular diagnostic products.
OmniSonics Medical Technologies is a U.S.-based company that develops medical devices used in the treatment of vascular occlusive diseases. Its products are designed to deliver transverse, ultrasonic energy along the length of a small diameter wire to an artery or vein that has been obstructed by thrombus. OmniSonics Medical Technologies uses low power ultrasonic energy to create cavitational streaming that rapidly dissolves thrombus and quickly restores blood flow without adversely damaging surrounding vessel walls. Its current commercial product, the OmniWave Endovascular System is indicated to infuse physician-specified fluids and remove thrombus in the peripheral vasculature. The company is headquartered in Lakewood, New York.

Fractyl Laboratories Inc.

Series F in 2022
Fractyl Laboratories Inc. develops a minimally invasive procedural therapy for metabolic diseases. It offers Revita DMR, a duodenal mucosal resurfacing therapy to rejuvenate the lining of the duodenum. Its Revita DMR procedure uses hydrothermal ablation to safely remove the excessive layer of the duodenal mucosa that develops due to high fat and sugar diets. Fractyl Laboratories Inc. was formerly known as MedCatalyst, Inc. and changed its name to Fractyl Laboratories Inc. in January 2012. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Zogenix

Series A in 2006
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Esperion Therapeutics

Venture Round in 2013
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

GenVault

Series A in 2003
GenVault is dedicated to stabilizing biosamples and to the integration of biosample transport, storage and retrieval, in a way that meshes seamlessly with day-to-day lab operations: thus simplifying sample sharing for customers in genomic medicine, discovery and identification. Today, we are empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement agencies, to more fully leverage the rapidly growing genomics industry. GenVault’s proprietary dry-state storage platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Currently work is proceeding on equivalent storage technologies for protein and RNA. The need for such sample management solutions is growing at an exponential rate, as more and more samples are collected worldwide for disease diagnosis, research, identification and criminal investigations

eNeura Therapeutics

Series A in 2002
ENeura Therapeutics is a medical technology company developing transcranial magnetic stimulation devices for the treatment of migraines. It pioneers the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go.

Orqis Medical

Series C in 2003
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

NovaCardia

Series B in 2007
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

RightCare Solutions, Inc.

Series A in 2012
RightCare Solutions employs evidence-based technology to help healthcare providers optimize their discharge planning process. With their proprietary Discharge Decision Support System, D2S2, hospitals, insurers, and homecare agencies improve the quality of care for patients while alleviating the devastating toll that 30-day re-admissions exact on the healthcare system. It was founded in 2011 and headquartered in Horsham, Pennsylvania.

CoLucid Pharmaceuticals

Series B in 2008
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

GeneOhm Sciences

Series C in 2004
GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

Benvenue Medical

Series D in 2012
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.
Tandem Diabetes Care, Inc. develops medical devices for the treatment of diabetes. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges. The company focuses on insulin infusion therapy. Tandem Diabetes Care, Inc. was incorporated in 2006 and is based in San Diego, California.

BioNano Genomics

Series C in 2013
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Nuon Therapeutics

Series B in 2008
Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Omniome

Series C in 2020
Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. Founded in 2013, the company is headquartered in San Diego, California, United States.

Sera Prognostics

Series A in 2011
Sera Prognostics, Inc., a biotechnology company, develops diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. It focuses on addressing the economic and healthcare burden that premature birth places on infants, their families, and society. Sera Prognostics, Inc. was founded in 2008 and is based in Salt Lake City, Utah.

Nobias Therapeutics

Series A in 2020
Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children. It focuses on discovering the genetic basis for rare diseases and develops drugs that can intervene in the affected pathways, enabling parents to help their infants become healthier.

Twelve

Venture Round in 2012
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Exalys Therapeutics

Series A in 2020
Exalys Therapeutics is developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with urgent unmet needs and limited treatment options. Exalys is initially targeting postoperative delirium, the most common complication of surgery in older patients and a key driver of poor health outcomes.
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.

Truvian Sciences

Series B in 2019
Truvian Sciences Inc develops automated diagnostic equipment which provides health test services. The company's product conducts blood test, immunoassays, and hematology assays. Its software system allows practitioners to deliver data to patients through a software platform. The company was incorporated in 2015 and is based in San Diego, California.

Conforma Therapeutics

Series C in 2003
Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Celator Pharmaceuticals

Series B in 2005
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

IntegenX

Series B in 2009
IntegenX, Inc. designs, manufactures, and markets automation systems that enable reliable microsample preparation and analysis for the life sciences. It offers Apollo 100, a platform that allows the processing of DNA sequencing reactions; Apollo 200, an integrated sample preparation system for human DNA identification; microfluidics for DNA sequencing, molecular diagnostics, and human identification applications; and Apollo 324 system, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation sequencing. The company was formerly known as Microchip Biotechnologies, Inc. and changed its name to IntegenX, Inc. in March 2010. The company was incorporated in 2003 and is based in Pleasanton, California.

Alimera Sciences, Inc.

Series C in 2008
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Antios Therapeutics

Series B in 2021
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Fractyl Laboratories Inc.

Series E in 2020
Fractyl Laboratories Inc. develops a minimally invasive procedural therapy for metabolic diseases. It offers Revita DMR, a duodenal mucosal resurfacing therapy to rejuvenate the lining of the duodenum. Its Revita DMR procedure uses hydrothermal ablation to safely remove the excessive layer of the duodenal mucosa that develops due to high fat and sugar diets. Fractyl Laboratories Inc. was formerly known as MedCatalyst, Inc. and changed its name to Fractyl Laboratories Inc. in January 2012. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

IntegenX

Series B in 2011
IntegenX, Inc. designs, manufactures, and markets automation systems that enable reliable microsample preparation and analysis for the life sciences. It offers Apollo 100, a platform that allows the processing of DNA sequencing reactions; Apollo 200, an integrated sample preparation system for human DNA identification; microfluidics for DNA sequencing, molecular diagnostics, and human identification applications; and Apollo 324 system, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation sequencing. The company was formerly known as Microchip Biotechnologies, Inc. and changed its name to IntegenX, Inc. in March 2010. The company was incorporated in 2003 and is based in Pleasanton, California.

Novalar Pharmaceuticals

Series C in 2005
Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

ROX Medical, Inc.

Series D in 2012
ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Tobira Therapeutics, Inc.

Series B in 2010
Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associated infectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.

NovaDigm Therapeutics

Series A in 2008
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.

SelfCare.com

Venture Round in 2000
SelfCare.com, a health and wellness e-commerce site for women and their families.

CoDa Therapeutics

Series B in 2012
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

BioNano Genomics

Series D in 2016
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Cerexa Inc.

Series A in 2005
Cerexa is a biopharmaceutical company focused on the development of a portfolio of novel anti-infective therapies for the treatment of serious and life-threatening infections. The company’s product portfolio includes Ceftaroline AcetateCeftaroline, an injectable cephalosporin that is used for the treatment of bacterial infections caused by gram-positive and gram-negative pathogens.

VIVUS, Inc.

Seed Round in 1991
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.

Aesthetic Sciences

Series A in 2006
Aesthetic Sciences Corp a Palo Alto, Calif.-based developer of injectable filler products for soft tissue augmentation.

Onyx Pharmaceuticals

Venture Round in 2002
Onyx Pharmaceuticals is a biopharmaceutical company committed to improving the lives of people with cancer. Their lead product is Nexavar (sorafenib), a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis.

Clovis Oncology, Inc.

Venture Round in 2009
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Esperion Therapeutics

Series A in 2008
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

aTyr Pharma, Inc.

Series C in 2010
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Kona Medical

Series C in 2012
Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

Optherion

Series A in 2007
Optherion, Inc., a biotechnology company, develops diagnostic and disease-modifying therapeutics for the management and treatment of early-stage age-related macular degeneration, dense deposit disease, atypical hemolytic uremic syndrome, and other chronic diseases involving the alternative complement cascade. The company was founded in 2005 and is based in New Haven, Connecticut.

Astute Medical, Inc.

Series C in 2012
Astute Medical, Inc., a life science tools company, discovers and develops protein biomarkers to serve as the basis for novel diagnostic tests for conditions that require rapid diagnosis and risk assessment. The company focuses on prognostic biomarker validation. It offers NephroCheck, a single use cartridge to detect biomarkers of acute kidney injury. The company also provides Astute140, a meter that converts fluorescent signal from NephroCheck test cartridge into a single numerical result. It sells its products in the United States and Europe. Astute Medical, Inc. was founded in 2007 and is based in San Diego, California with a location in Paris, France. As of April 4, 2018, Astute Medical, Inc. operates as a subsidiary of bioMérieux S.A.

Epic Sciences, Inc.

Series D in 2017
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Omniome

Series B in 2018
Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. Founded in 2013, the company is headquartered in San Diego, California, United States.

Align Technology, Inc.

Venture Round in 1999
Align Technology, Inc. designs, manufactures, and markets the invisalign system for treating malocclusion or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. The company's products include Invisalign Full for the treatment of a range of malocclusions; Invisalign Express, a solution for less complex orthodontic cases; Invisalign Teen, which is designed to meet the specific needs of the non-adult comprehensive or teen treatment market; Vivera retainers that offer aesthetic retention solution for invisalign and non-invisalign patients; and Invisalign Assist, which is designed for general practitioners for selecting, monitoring, and finishing invisalign cases. It also offers ancillary products comprising cleaning material and adjusting tools for dental professionals. Align Technology distributes its products directly to orthodontists and general practitioner dentists in North America, Europe, the Asia Pacific, Latin America, and Japan. The company was founded in 1997 and is headquartered in Santa Clara, California.

Corthera

Series B in 2004
Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.

Volcano Corporation

Venture Round in 2001
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Their products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information using sound as a guiding element.

Corridor Pharmaceuticals

Series A in 2010
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

Celladon

Series B in 2005
Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.

NeuroPace

Venture Round in 2005
NeuroPace, Inc. designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders with responsive stimulation. It offers RNS System, a medical device that monitors and responds to brain activity. The company’s RNS System consists of a small implantable neuro stimulator that is connected to leads that are placed in up to two seizure onset areas. NeuroPace, Inc. was founded in 1997 and is based in Mountain View, California.

Asmacure Ltée

Series A in 2007
Asmacure Ltée, a clinical-stage biopharmaceutical company, focuses on the development of proprietary molecules that target cholinergic receptors for the treatment of inflammation (primarily pulmonary airway diseases). It develops ASM-024 for the treatment of moderate asthma and chronic obstructive pulmonary disease with a dry powder for inhalation formulation. The company was founded in 2002 and is based in Quebec City, Canada. As of August 19, 2015, Asmacure Ltée operates as a subsidiary of Odan Laboratories Ltd.

Fractyl Laboratories Inc.

Series D in 2017
Fractyl Laboratories Inc. develops a minimally invasive procedural therapy for metabolic diseases. It offers Revita DMR, a duodenal mucosal resurfacing therapy to rejuvenate the lining of the duodenum. Its Revita DMR procedure uses hydrothermal ablation to safely remove the excessive layer of the duodenal mucosa that develops due to high fat and sugar diets. Fractyl Laboratories Inc. was formerly known as MedCatalyst, Inc. and changed its name to Fractyl Laboratories Inc. in January 2012. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Vascular Architects

Series E in 2004
Vascular Architects, Inc. designs, develops, manufactures and markets devices used in the treatment of vascular stenoses, occlusions and non-vascular obstructions. A key area of emphasis is the treatment of peripheral vascular disease, which manifests itself as a reduction or loss of blood flow due to the narrowing or closing of arteries. Vascular Architects was founded in October 1997 by Thomas J. Fogarty, M.D. Dr Fogarty is an internationally renowned surgeon, professor, inventor and entrepreneur who has founded or cofounded more than 25 start-up companies that develop innovative medical devices. He has authored or coauthored over 150 professional articles, is a member of 29 professional societies, and is an inventor on more than 65 U.S. patents. Their founder and management team form a highly experienced group of technical, clinical and business personnel. Key opinion leaders in the interventional and vascular surgery communities have been recruited to serve on the Vascular Architects' Scientific Advisory Board.

Sequent Medical

Series C in 2012
Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.

Zogenix

Series B in 2008
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Zogenix

Series B in 2009
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

aTyr Pharma, Inc.

Series E in 2015
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Astute Medical, Inc.

Series B in 2010
Astute Medical, Inc., a life science tools company, discovers and develops protein biomarkers to serve as the basis for novel diagnostic tests for conditions that require rapid diagnosis and risk assessment. The company focuses on prognostic biomarker validation. It offers NephroCheck, a single use cartridge to detect biomarkers of acute kidney injury. The company also provides Astute140, a meter that converts fluorescent signal from NephroCheck test cartridge into a single numerical result. It sells its products in the United States and Europe. Astute Medical, Inc. was founded in 2007 and is based in San Diego, California with a location in Paris, France. As of April 4, 2018, Astute Medical, Inc. operates as a subsidiary of bioMérieux S.A.

Evofem Biosciences

Series C in 2014
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Otonomy, Inc.

Series C in 2013
Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

IntraLase Corporation

Venture Round in 2000
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Obalon Therapeutics, Inc.

Series C in 2012
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize the treatment of chronic disease. As a company, they believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives. It was founded in 2008.

Cabrellis Pharmaceuticals

Series A in 2006
Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

Dicerna Pharmaceuticals

Series C in 2013
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

Celator Pharmaceuticals

Series D in 2010
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

Veracyte

Private Equity Round in 2012
Veracyte, Inc. develops diagnostics for thyroid and non-small cell lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. The company was incorporated in 2006 and is based in South San Francisco, California.

Medpool

Venture Round in 1999
Medpool is a healthcare company that is using the Internet to provide a unique pooling and interactive contract negotiation tool between buyers and sellers of medical equipment, supplies, and services. As a market maker, it has filed several patents on its business model. Buyers' purchasing power is pooled together on a virtual trading floor to collectively purchase medical equipment, supplies, and services for the best value. Selected sellers have the ability to capture large volumes of new business, retain at-risk business, and reduce operating costs. Medpool automates this process. The Medpool contracting marketplace benefits both sellers and buyers by allowing sellers to differentiate their products and receive committed business while buyers benefit from the volume pricing and streamlined purchasing process.

CoLucid Pharmaceuticals

Series C in 2015
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

Achaogen

Series D in 2013
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

SkinMedica

Series D in 2004
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

Ansata Therapeutics

Series B in 2003
Ansata Therapeutics is a biopharmaceutical company engaged in the development and commercialization of topical drugs for dermatologic indications. It was founded in 2002 and is based in La Jolla, California.

Nuon Therapeutics

Venture Round in 2010
Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Applied Proteomics

Series B in 2012
Applied Proteomics, Inc. develops noninvasive and blood-based tests that provide the proteins for monitoring and early detection of disease. It offers SimpliPro Colon test to deliver tests. The company was founded in 2006 and is based in San Diego, California.

ReVision Optics

Series D in 2007
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

NovaCardia

Series B in 2006
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

Apnex Medical

Series B in 2009
Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

Smart Medical Systems

Venture Round in 2014
Smart Medical Systems Ltd. develops, manufactures, and commercializes medical devices specializing in the field of gastroenterology and gastrointestinal (GI) endoscopy. The company offers NaviAid Platform designed to overcome the challenges in GI endoscopy; G-EYE endoscope that enables Controlled Withdrawal of the endoscope during colonoscopy, improving visibility of the colon and making therapy and intervention easier and faster; NaviAid AB (Advancing Balloon) device that provides ileoscopy/upper enteroscopy while using standard endoscopes; NaviAid ABC (Advancing Balloon for Colonoscopy) device for colonoscopy; NaviAid inflation systems that facilitate the operation of various balloon devices within the gastrointestinal tract; and Controlled Withdrawal technique, a feature of the G-EYE endoscope and the NaviAid family that enables a thorough investigation of the bowel, improving visibility, detection, and stability of the endoscope. It serves customers through distributors in the United States and Europe. The company is based in Ra’anana, Israel with a subsidiary operation in the United States.

Alimera Sciences, Inc.

Series A in 2004
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Orexigen Therapeutics

Series A in 2004
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The company's Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.

Glaukos Corporation

Series F in 2013
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

ReVision Optics

Series E in 2013
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

CoLucid Pharmaceuticals

Venture Round in 2011
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

ESP Pharma

Series B in 2003
ESP Pharma is a hospital-focused pharmaceutical company, engages in acquiring and enhancing the marketing of approved specialty therapeutics and late-stage development drugs. It provides therapeutics to physicians, hospitals, and acute-care patients. ESP produces drugs for acute-care hospital use. Its drugs include therapeutics for high blood pressure and angina.

Miramar Labs

Series D in 2014
Miramar Labs develops medical devices for aesthetic indications that treat primary axillary (underarm) hyperhidrosis in adults. The miraDry System cannot be used to treat hyperhidrosis elsewhere on the body, including the hands and feet. It was founded in 2006 and is based in Sunnyvale, California.

GenVault

Series A in 2005
GenVault is dedicated to stabilizing biosamples and to the integration of biosample transport, storage and retrieval, in a way that meshes seamlessly with day-to-day lab operations: thus simplifying sample sharing for customers in genomic medicine, discovery and identification. Today, we are empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement agencies, to more fully leverage the rapidly growing genomics industry. GenVault’s proprietary dry-state storage platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Currently work is proceeding on equivalent storage technologies for protein and RNA. The need for such sample management solutions is growing at an exponential rate, as more and more samples are collected worldwide for disease diagnosis, research, identification and criminal investigations

Carticept Medical

Series C in 2012
Carticept Medical develops therapies to improve the quality of life of patients with osteoarthritis or cartilage damage. Carticept currently offers a cartilage implant product and distributes Sonosite ultrasound products.

Twelve

Series C in 2015
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

iScribe

Series B in 2000
iScribe is a healthcare technology company that is focused on the development of mobile, handheld, and wireless electronic prescribing technology solutions. iScribe was founded by David Levison in 1999.

Orqis Medical

Series D in 2007
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

Sequent Medical

Series B in 2010
Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.

Apnex Medical

Series C in 2012
Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

Benvenue Medical

Series C in 2011
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

Corthera

Series A in 2003
Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.

Zyga Technology, Inc.

Series D in 2014
Zyga Technology is a surgical solutions provider developing & commercializing medical devices for treating spine problems. In addition to the SImmetry Sacroiliac Joint Fusion System, the company is also developing the Glyder Facet Restoration Device. Zyga has put together a team of engineers, marketing personnel, and management with significant experience developing medical devices for the spine industry. Zyga Technology was founded in 2008 and is headquartered in Minnesota, USA.

Ocera Therapeutics

Series C in 2008
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

CoLucid Pharmaceuticals

Series A in 2006
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

GenVault

Series A in 2003
GenVault is dedicated to stabilizing biosamples and to the integration of biosample transport, storage and retrieval, in a way that meshes seamlessly with day-to-day lab operations: thus simplifying sample sharing for customers in genomic medicine, discovery and identification. Today, we are empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement agencies, to more fully leverage the rapidly growing genomics industry. GenVault’s proprietary dry-state storage platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Currently work is proceeding on equivalent storage technologies for protein and RNA. The need for such sample management solutions is growing at an exponential rate, as more and more samples are collected worldwide for disease diagnosis, research, identification and criminal investigations

TargetRx

Series D in 2005
TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.

BiPar Sciences

Series B in 2007
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

IntegenX

Series C in 2011
IntegenX, Inc. designs, manufactures, and markets automation systems that enable reliable microsample preparation and analysis for the life sciences. It offers Apollo 100, a platform that allows the processing of DNA sequencing reactions; Apollo 200, an integrated sample preparation system for human DNA identification; microfluidics for DNA sequencing, molecular diagnostics, and human identification applications; and Apollo 324 system, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation sequencing. The company was formerly known as Microchip Biotechnologies, Inc. and changed its name to IntegenX, Inc. in March 2010. The company was incorporated in 2003 and is based in Pleasanton, California.

BioNano Genomics

Series B in 2011
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Senomyx, Inc.

Series B in 2000
Senomyx is using proprietary taste receptor technologies to discover and develop novel flavor ingredients. These include new flavors such as Savory Flavors and Cooling Flavors, as well as flavor modulators such as Bitter Blockers and enhancers of Sweet and Salt tastes. Senomyx is also engaged in a new effort to discover and develop natural high-potency sweeteners.

ReVision Optics

Series D in 2010
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Novacea

Series B in 2002
As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

Sequent Medical

Series D in 2014
Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.
VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.

Zogenix

Venture Round in 2010
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Zyga Technology, Inc.

Series C in 2012
Zyga Technology is a surgical solutions provider developing & commercializing medical devices for treating spine problems. In addition to the SImmetry Sacroiliac Joint Fusion System, the company is also developing the Glyder Facet Restoration Device. Zyga has put together a team of engineers, marketing personnel, and management with significant experience developing medical devices for the spine industry. Zyga Technology was founded in 2008 and is headquartered in Minnesota, USA.

IntraLens Vision

Venture Round in 2016
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Immune Control

Series A in 2005
Immune Control, Inc. was formed in 2001 based on technology developed in the laboratories of Professors Bradford Jameson and Ana Tretiakova, Department of Biochemistry, Drexel University College of Medicine. Initial funding came from Argil Management, LLC, of Boston. In 2003, Stephen Roth, Ph.D., became president and CEO of Immune Control. The Company plans to complete an investigational new drug (IND) application to be submitted to the Food and Drug Agency in 2005. The IND application will propose the use of an already marketed serotonin antagonist in multiple myeloma patients in a small, and relatively short, phase 1/2 clinical trial. If the drug has significant, clinical efficacy against the malignant B cells characteristic of multiple myeloma, they would immediately begin plans for a larger, phase 3 trial. Positive results in the first trial would constitute clinical proof-of-concept for the Company's basic premise-that serotonin antagonists have clinical utility against inappropriately activated immune cells. Another Company goal focuses on proprietary serotonin antagonists that are more potent than those already approved, and that do not cross the blood-brain barrier, making them free of adverse neurological side-effects. Such new chemical entities would be screened for their abilities to bind to specific immunological serotonin receptors, which are now being characterized. The Company has made progress with at least two receptors, one of which has apparently not previously been described. Research on the molecular biology of the receptors is underway at Drexel University College of Medicine, and new chemical entities to be screened for serotonin antagonist activity are being synthesized for the Company. Ultimately, they hope to find compounds that can be used against many hematologic cancers, transplant rejection, and against a host of diseases that are all caused by inappropriate lymphocyte activation. Examples of such diseases are type I diabetes, rheumatoid arthritis, lupus, asthma, and many of the muscular dystrophies. The market size for drugs that treat each of these conditions exceeds a billion dollars. Simultaneously, the Company aggressively protects its intellectual property with patent applications. Novel use applications, novel compound applications, and novel receptor applications are all examples of the Company's existing IP portfolio, which has been licensed exclusively and worldwide to the Company by Drexel University.

Benvenue Medical

Series F in 2016
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

GI Dynamics

Series C in 2009
GI Dynamics, Inc., a medical device company, designs, develops, manufactures, and markets medical devices for non-surgical approaches to treat type 2 diabetes and obesity. The company offers EndoBarrier, a medical device for the treatment of patients with type 2 diabetes and reduction of obesity. It serves health care providers and third-party distributors. The company sells its products primarily in Europe, the Middle East, the Asia Pacific, and South America. GI Dynamics, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

DiObex

Series A in 2005
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.

Obalon Therapeutics, Inc.

Series E in 2016
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize the treatment of chronic disease. As a company, they believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives. It was founded in 2008.

Achaogen

Series C in 2010
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

Celtaxsys

Series D in 2015
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

ReVision Optics

Series E in 2013
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Ascenta Therapeutics

Series B in 2004
Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

Imagine Pharmaceuticals

Series A in 2004
Imagine Pharma is a drug discovery and development company that focuses on innovative regenerative approaches to therapeutic drugs for diabetes and cardiovascular disease. Their agile, creative and efficient approach to drug discovery is designed to find therapeutics that significantly improve on the efficacy and safety of existing treatments.

BioVascular

Series C in 2008
BioVascular is a clinical stage privately held biotechnology company developing “first in class” products for platelet mediated cardiovascular diseases. BioVascular’s initial product, saratin, is a polypeptide produced by recombinant means in yeast. This product was discovered by and licensed from Merck KGaA. BioVascular is conducting human clinical trials of saratin for use in hemodialysis access graft and peripheral artery grafts to reduce intimal hyperplasia, which can lead to failure of the graft.

NeuroPace

Venture Round in 2011
NeuroPace, Inc. designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders with responsive stimulation. It offers RNS System, a medical device that monitors and responds to brain activity. The company’s RNS System consists of a small implantable neuro stimulator that is connected to leads that are placed in up to two seizure onset areas. NeuroPace, Inc. was founded in 1997 and is based in Mountain View, California.

Viagene Inc

Seed Round in 1987
Viagene Inc is a Florida based company, play a vital role in improving molecular and cell biology research worldwide.

Orexigen Therapeutics

Series B in 2005
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The company's Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.

Neuron Systems

Series A in 2008
Mass.-based drug developer for treatment of retinal diseases.

Sera Prognostics

Series B in 2015
Sera Prognostics, Inc., a biotechnology company, develops diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. It focuses on addressing the economic and healthcare burden that premature birth places on infants, their families, and society. Sera Prognostics, Inc. was founded in 2008 and is based in Salt Lake City, Utah.

Xagenic Inc.

Series B in 2014
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing a new technology for decentralized, rapid diagnostic testing and a true point-of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.

SkinMedica

Series E in 2005
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

Axial Biotherapeutics

Series A in 2016
Axial Biotherapeutics, Inc., a biopharmaceutical company, develops therapeutics for people with central nervous system diseases and disorders. It uses the microbiome discovery platform, which targets the gut-brain axis that provides the opportunity to generate a pipeline of new therapies for patients with neurological diseases and disorders. Axial Biotherapeutics, Inc. was formerly known as Neurobiotix Health, Inc. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Singular Genomics

Seed Round in 2016
Singular Genomics is a venture capital-backed biotech company in La Jolla, California. It fosters a dynamic, fast-paced, results-oriented environment where they offer employees the opportunity to make a significant impact in a rapidly expanding company. Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. The company is located in the center of the Biotech hub on the Torrey Mesa close to the Pacific Ocean and next door to prestigious institutions like the Salk Institute, Scripps, Sanford Burnham, and UCSD.

NuVasive

Venture Round in 2004
NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market. NuVasive’s principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform’s lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With over 80 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.

SkinMedica

Series B in 2002
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

Fractyl Laboratories Inc.

Series C in 2015
Fractyl Laboratories Inc. develops a minimally invasive procedural therapy for metabolic diseases. It offers Revita DMR, a duodenal mucosal resurfacing therapy to rejuvenate the lining of the duodenum. Its Revita DMR procedure uses hydrothermal ablation to safely remove the excessive layer of the duodenal mucosa that develops due to high fat and sugar diets. Fractyl Laboratories Inc. was formerly known as MedCatalyst, Inc. and changed its name to Fractyl Laboratories Inc. in January 2012. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Epic Sciences, Inc.

Series C in 2014
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.

BioNano Genomics

Series C in 2014
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Regado Biosciences

Series C in 2007
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.

TargetRx

Series C in 2001
TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.

Oraya Therapeutics

Series C in 2009
Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye.

CoDa Therapeutics

Series A in 2006
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

TargetRx

Series C in 2003
TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.

ROX Medical, Inc.

Series C in 2008
ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Santarus

Series D in 2003
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

ChromaCode

Series B in 2017
ChromaCode is a molecular diagnostics company focusing on bioinformatics. It leverages patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation. The company uses this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost. ChromaCode was founded in 2012, ChromaCode is headquartered in Carlsbad, California.

Altea Therapeutics

Series B in 2002
Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.
WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The company leveraging its proprietary platform to develop a novel class of cell therapies called MILs (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow. WindMIL Therapeutics was established in 2015 and is based in Baltimore, MD.
VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.

3F Therapeutics

Series B in 2004
3F Therapeutics develops, manufactures, and markets cardiovascular devices. It offers invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system to reduce surgical cross-clamp and cardio-pulmonary bypass time, utilization for congestive heart failure.

Cardiodynamics International

Venture Round in 1999
CardioDynamics International develops, manufactures, and markets noninvasive impedance cardiography diagnostic and monitoring devices, and proprietary ICG sensors. The company’s product line primarily includes BioZ Dx, BioZ ICG Monitor, BioZ ICG Module, associated BioZtect sensors, Niccomo and Cardioscreen monitor, Rheoscreen measurement devices, and more. CardioDynamics was founded in 1980 and is headquartered in San Diego, California.

Pharmion

Venture Round in 2001
Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Ariosa Diagnostics, Inc.

Series C in 2012
Ariosa Diagnostics, Inc. (formerly Aria Diagnostics (formerly known as Tandem Diagnostics)), a San Jose, Calif.-based molecular diagnostics company.
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Ocera Therapeutics

Series B in 2006
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

Proxima Therapeutics

Series E in 2002
Proxima Therapeutics develops radiation delivery systems for the treatment of solid cancerous tumors, with an initial focus on brain and breast cancer. Founded in 1996, the company’s marketed products include GliaSite RTS for brain cancer and MammoSite RTS for breast cancer. Proxima Therapeutics was acquired by Cytec Industries Inc. in 2005.

Twelve

Series A in 2010
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Celator Pharmaceuticals

Series C in 2008
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

aTyr Pharma, Inc.

Series D in 2013
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Glaukos Corporation

Series A in 2002
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Genta

Venture Round in 1991
Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of people with cancer. Genta has built a broad portfolio of proprietary products in various stages of clinical development. The Company’s drugs include Ganite (gallium nitrate injection), tesetaxel, and oral gallium.

REVA Medical

Venture Round in 2007
Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage the Company's proprietary biomaterial and stent technologies to improve the treatment of disease. Guided by a management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA's initial focus is the development of an innovative drug-eluting bioresorbable coronary stent and the commencement of clinical studies that will advance the treatment of coronary artery disease.

GenVault

Venture Round in 2007
GenVault is dedicated to stabilizing biosamples and to the integration of biosample transport, storage and retrieval, in a way that meshes seamlessly with day-to-day lab operations: thus simplifying sample sharing for customers in genomic medicine, discovery and identification. Today, we are empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement agencies, to more fully leverage the rapidly growing genomics industry. GenVault’s proprietary dry-state storage platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Currently work is proceeding on equivalent storage technologies for protein and RNA. The need for such sample management solutions is growing at an exponential rate, as more and more samples are collected worldwide for disease diagnosis, research, identification and criminal investigations

Apnex Medical

Series A in 2007
Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

Celator Pharmaceuticals

Series C in 2007
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

Afferent Pharmaceuticals

Series A in 2009
Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.

Sonexa Therapeutics

Series A in 2008
Sonexa Therapeutics, Inc., a pharmaceutical company, engages in the development of therapeutics drugs for the treatment of Alzheimer's disease and related disorders. It develops ST101, a small and orally active molecule compound that penetrates the blood-brain-barrier. The company was incorporated in 2007 and is based in San Diego, California.

Seraphina Therapeutics

Series A in 2020
Seraphina Therapeutics, Inc., a health and wellness company, develops therapeutic to treat comorbidities of aging and to slow the rate of aging to help people live longer. It offers fatty acid supplements, micronutrients, food fortifiers, and nutritional interventions to counter age-related breakdown. The company was incorporated in 2017 and is based in San Diego, California.

Milestone Pharmaceuticals

Series B in 2015
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.

Esprit Pharma

Series B in 2006
Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.

Five Prime Therapeutics, Inc.

Venture Round in 2005
FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap and Advanced Tech­nol­ogy Ventures.

Novacea

Series C in 2004
As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

TargetRx

Series B in 2000
TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.

Tobira Therapeutics, Inc.

Series A in 2007
Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associated infectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.

Kona Medical

Debt Financing in 2015
Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

Atara Biotherapeutics

Series B in 2014
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Novalar Pharmaceuticals

Series B in 2003
Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

Otonomy, Inc.

Series B in 2010
Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

SenoRx

Venture Round in 2001
SenoRx, Inc. was formerly known as BiopSolation Medical, Inc. and changed its name to SenoRx, Inc. in April 1998. The company was incorporated in 1998 and is headquartered in Irvine, California. As of July 6, 2010, SenoRx, Inc. operates as a subsidiary of Bard Peripheral Vascular, Inc. They develop, manufacture and sell minimally-invasive medical devices for the diagnosis of breast cancer. Their initial product focus has been biopsy systems and breast tissue markers. They also are developing products for use in the treatment of breast cancer.

Peninsula Pharmaceuticals

Series C in 2004
A bio­pharmaceuti­cal company focused on the devel­opment and com­mer­cializa­tion of antibi­otics

Pointshare

Series B in 1999
Pointshare is a national leader in connecting local healthcare communities with secure, online business services that enhance communication, create efficiencies, and improve the delivery of care. Pointshare is the only company that has developed the technology, infrastructure, and hands-on service to create a proven, practical solution for automating the day-to-day business transactions of healthcare.

CellBiosciences

Series F in 2010
ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

Regado Biosciences

Series D in 2009
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.

BiPar Sciences

Series C in 2009
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

Afferent Pharmaceuticals

Venture Round in 2013
Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.

Epic Sciences, Inc.

Series E in 2018
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Obalon Therapeutics, Inc.

Series D in 2015
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize the treatment of chronic disease. As a company, they believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives. It was founded in 2008.

Esprit Pharma

Series A in 2005
Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.

Verus Pharmaceuticals

Series A in 2005
Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.

Xagenic Inc.

Series B in 2015
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing a new technology for decentralized, rapid diagnostic testing and a true point-of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.

Proxima Therapeutics

Series D in 2001
Proxima Therapeutics develops radiation delivery systems for the treatment of solid cancerous tumors, with an initial focus on brain and breast cancer. Founded in 1996, the company’s marketed products include GliaSite RTS for brain cancer and MammoSite RTS for breast cancer. Proxima Therapeutics was acquired by Cytec Industries Inc. in 2005.

Glaukos Corporation

Series D in 2008
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Regado Biosciences

Series E in 2012
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.

Epic Sciences, Inc.

Series B in 2012
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

ChromaCode

Series C in 2019
ChromaCode is a molecular diagnostics company focusing on bioinformatics. It leverages patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation. The company uses this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost. ChromaCode was founded in 2012, ChromaCode is headquartered in Carlsbad, California.

Nuon Therapeutics

Venture Round in 2010
Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Antios Therapeutics

Series A in 2018
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Milestone Pharmaceuticals

Series D in 2018
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

eNeura Therapeutics

Series B in 2005
ENeura Therapeutics is a medical technology company developing transcranial magnetic stimulation devices for the treatment of migraines. It pioneers the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go.

Neose Technologies, Inc

Venture Round in 2003
Neose Technologies, Inc. operates under a plan of liquidation that was approved in January 2009. Previously, the company operated as a clinical-stage biopharmaceutical company that focused on the development of next-generation therapeutic proteins. The company’s products were developed based on the GlycoPEGylation technology that involved the use of enzymes to attach PEG to carbohydrate structures on proteins. Its therapeutic protein candidates in development stage included GlycoPEG-GCSF, a phase-I completed product, for the treatment of neutropenia associated with myelosuppressive chemotherapy; and GlycoPEG-FVIIa for the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. Neose Technologies, Inc. was founded in 1989 and is headquartered in Horsham, Pennsylvania

Carticept Medical

Series B in 2010
Carticept Medical develops therapies to improve the quality of life of patients with osteoarthritis or cartilage damage. Carticept currently offers a cartilage implant product and distributes Sonosite ultrasound products.

Astute Medical, Inc.

Series B in 2011
Astute Medical, Inc., a life science tools company, discovers and develops protein biomarkers to serve as the basis for novel diagnostic tests for conditions that require rapid diagnosis and risk assessment. The company focuses on prognostic biomarker validation. It offers NephroCheck, a single use cartridge to detect biomarkers of acute kidney injury. The company also provides Astute140, a meter that converts fluorescent signal from NephroCheck test cartridge into a single numerical result. It sells its products in the United States and Europe. Astute Medical, Inc. was founded in 2007 and is based in San Diego, California with a location in Paris, France. As of April 4, 2018, Astute Medical, Inc. operates as a subsidiary of bioMérieux S.A.
Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs. The company has assembled an experienced team along with a portfolio of clinical and commercial stage programs with the goal of bringing important new treatment options to patients.

OraPharma Inc. (acquired by JNJ)

Venture Round in 1998
OraPharma is a specialty pharmaceutical company that develops and commercializes products that help improve and maintain oral health. They are dedicated to delivering scientifically and technologically advanced products to dental professionals and their practices. ARESTIN® (minocycline HCl) Microspheres, 1 mg is a locally administered antibiotic (LAA) offering a patented microsphere technology. OraPharma is proud to have introduced this revolutionary approach to treating periodontitis as an adjunct to scaling and root planing and continues to take a leadership role in educating clinicians and consumers on the disease. Read more about ARESTIN® or click here for Prescribing Information.

Axial Biotherapeutics

Series B in 2019
Axial Biotherapeutics, Inc., a biopharmaceutical company, develops therapeutics for people with central nervous system diseases and disorders. It uses the microbiome discovery platform, which targets the gut-brain axis that provides the opportunity to generate a pipeline of new therapies for patients with neurological diseases and disorders. Axial Biotherapeutics, Inc. was formerly known as Neurobiotix Health, Inc. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

ROX Medical, Inc.

Series E in 2016
ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Obalon Therapeutics, Inc.

Series A in 2008
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize the treatment of chronic disease. As a company, they believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives. It was founded in 2008.
Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. Cantex is currently conducting two unique development programs with modified versions of two separate known chemical entities each of which addresses major unmet medical needs representing high-value market opportunities:

Novalar Pharmaceuticals

Series D in 2007
Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

BioNano Genomics

Series D in 2016
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Benvenue Medical

Series E in 2014
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

Otonomy, Inc.

Series D in 2014
Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

GelTex Pharmaceutics

Venture Round in 1993
GelTex Pharmaceutics develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. It also develops small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators. Its focus areas include hyperphosphatemia, hypercholesterolemia, cancer, iron overload, and infectious diseases. GelTex Pharmaceutics is based in Waltham Massachusetts.

Fractyl Laboratories Inc.

Series B in 2014
Fractyl Laboratories Inc. develops a minimally invasive procedural therapy for metabolic diseases. It offers Revita DMR, a duodenal mucosal resurfacing therapy to rejuvenate the lining of the duodenum. Its Revita DMR procedure uses hydrothermal ablation to safely remove the excessive layer of the duodenal mucosa that develops due to high fat and sugar diets. Fractyl Laboratories Inc. was formerly known as MedCatalyst, Inc. and changed its name to Fractyl Laboratories Inc. in January 2012. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Sera Prognostics

Series B in 2014
Sera Prognostics, Inc., a biotechnology company, develops diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. It focuses on addressing the economic and healthcare burden that premature birth places on infants, their families, and society. Sera Prognostics, Inc. was founded in 2008 and is based in Salt Lake City, Utah.

3F Therapeutics

Series C in 2005
3F Therapeutics develops, manufactures, and markets cardiovascular devices. It offers invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system to reduce surgical cross-clamp and cardio-pulmonary bypass time, utilization for congestive heart failure.

GI Dynamics

Series B in 2004
GI Dynamics, Inc., a medical device company, designs, develops, manufactures, and markets medical devices for non-surgical approaches to treat type 2 diabetes and obesity. The company offers EndoBarrier, a medical device for the treatment of patients with type 2 diabetes and reduction of obesity. It serves health care providers and third-party distributors. The company sells its products primarily in Europe, the Middle East, the Asia Pacific, and South America. GI Dynamics, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Altair Therapeutics

Series B in 2010
Altair Therapeutics is a biopharmaceutical company focused on developing therapeutics to treat human respiratory diseases.

NovaCardia

Venture Round in 2003
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

Kalidex Pharmaceuticals

Venture Round in 2012
Kalidex Pharmaceuticals, Inc. manufactures pharmaceuticals. The company was incorporated in 2010 and is based in Menlo Park, California.

Ascenta Therapeutics

Series C in 2007
Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

ROX Medical, Inc.

Series B in 2006
ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Iterum Therapeutics plc

Series B in 2017
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

GI Dynamics

Series A in 2003
GI Dynamics, Inc., a medical device company, designs, develops, manufactures, and markets medical devices for non-surgical approaches to treat type 2 diabetes and obesity. The company offers EndoBarrier, a medical device for the treatment of patients with type 2 diabetes and reduction of obesity. It serves health care providers and third-party distributors. The company sells its products primarily in Europe, the Middle East, the Asia Pacific, and South America. GI Dynamics, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

CellBiosciences

Series B in 2006
ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

Aspen Neuroscience

Series A in 2020
Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.

Milestone Pharmaceuticals

Series C in 2017
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.

Sequel Pharmaceuticals

Series A in 2007
Sequel Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease. The company was founded in 2007 and is based in San Diego, California.

Evofem Biosciences

Series C in 2012
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Tragara

Series A in 2007
Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

NovaCardia

Series A in 2005
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

Sebacia, Inc.

Series D in 2017
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.

Medpool

Venture Round in 2000
Medpool is a healthcare company that is using the Internet to provide a unique pooling and interactive contract negotiation tool between buyers and sellers of medical equipment, supplies, and services. As a market maker, it has filed several patents on its business model. Buyers' purchasing power is pooled together on a virtual trading floor to collectively purchase medical equipment, supplies, and services for the best value. Selected sellers have the ability to capture large volumes of new business, retain at-risk business, and reduce operating costs. Medpool automates this process. The Medpool contracting marketplace benefits both sellers and buyers by allowing sellers to differentiate their products and receive committed business while buyers benefit from the volume pricing and streamlined purchasing process.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

RightCare Solutions, Inc.

Series B in 2013
RightCare Solutions employs evidence-based technology to help healthcare providers optimize their discharge planning process. With their proprietary Discharge Decision Support System, D2S2, hospitals, insurers, and homecare agencies improve the quality of care for patients while alleviating the devastating toll that 30-day re-admissions exact on the healthcare system. It was founded in 2011 and headquartered in Horsham, Pennsylvania.

GenVault

Series B in 2008
GenVault is dedicated to stabilizing biosamples and to the integration of biosample transport, storage and retrieval, in a way that meshes seamlessly with day-to-day lab operations: thus simplifying sample sharing for customers in genomic medicine, discovery and identification. Today, we are empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement agencies, to more fully leverage the rapidly growing genomics industry. GenVault’s proprietary dry-state storage platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Currently work is proceeding on equivalent storage technologies for protein and RNA. The need for such sample management solutions is growing at an exponential rate, as more and more samples are collected worldwide for disease diagnosis, research, identification and criminal investigations